Normal glycosylated hemoglobin masking glucose dysregulation in a patient with pancreatic and hematologic disease
Abstract
Although hemoglobin A1c (HbA1c) is widely used to assess long-term glycemia, its reliability declines in conditions that alter red blood cell turnover or hemoglobin glycation. Pancreatic structural diseases, including pancreatic neuroendocrine tumors (pNETs) and intraductal papillary mucinous neoplasms (IPMNs), may further affect glucose regulation through impaired endocrine function. Systemic inflammation and specific hematologic conditions can also create discordant glycemic markers, complicating diagnosis, and management. We report a 59-year-old woman with autoimmune disease who presented with fatigue and fluctuating glucose levels. Her HbA1c remained within normal limits; however, continuous glucose monitoring (CGM) and an oral glucose tolerance test (OGTT) demonstrated marked hyperglycemia. Imaging revealed pancreatic lesions concerning for a pNET in the setting of known IPMNs. Laboratory evaluation was notable for elevated ferritin and clonal hematopoiesis of indeterminate potential (CHIP). Additional studies, including hemoglobin, albumin, renal and hepatic function, and hemoglobin electrophoresis, were normal, ruling out anemia and hemoglobinopathies. Her glycemic discordance likely reflects impaired insulin secretion due to pancreatic pathology combined with inflammation driven alterations in erythrocyte lifespan associated with CHIP. This case underscores the limitations of HbA1c in complex metabolic or inflammatory states and highlights the value of CGM and OGTT…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.